Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02628067
Title Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

bile duct carcinoma

lung small cell carcinoma

thyroid gland carcinoma

Advanced Solid Tumor

malignant mesothelioma

cholangiocarcinoma

salivary gland cancer

endometrial carcinoma

gallbladder adenocarcinoma

neuroendocrine tumor

cervix carcinoma

vulva carcinoma

anal canal carcinoma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.